Business Context and Reporting Period
Company: Microbot Medical Inc. (NASDAQ: MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: January 6, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Registered Offering: Sale of 4,000,001 shares of Common Stock at $1.75 per share.
- Gross Proceeds: Approximately $7.0 million (before fees and expenses).
- Concurrent Private Placement: Issuance of Series G Warrants to purchase up to 8,000,002 shares of Common Stock.
- Warrant Terms: Exercise price of $1.75 per share; exercisable immediately; expire two years from the initial exercise date.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive a 7.0% cash fee plus a 1.0% management fee on gross proceeds, plus $25,000 non-accountable expenses and up to $35,000 for legal counsel.
- Agent Warrants: 200,000 Wainwright Warrants issued with an exercise price of $2.1875 per share.
Material Changes and Restrictions
The filing outlines specific restrictions and structural changes resulting from the transaction:
- Issuance Restrictions: The Company agreed to restrictions on issuing Common Stock or Common Stock Equivalents for 30 days following the closing.
- Ownership Caps: Holders are restricted from exercising warrants if it results in ownership exceeding 4.99% (or 9.99% at the purchaser's option) of outstanding Common Stock. A 61-day notice period allows holders to increase this cap from 4.99% to 9.99%.
- Future Financing Fees: Wainwright is entitled to a 7.0% cash fee and 5.0% warrant coverage on any future cash exercises of the Series G Warrants.
- Right of First Refusal: Wainwright holds a right of first refusal for equity or debt financings for 12 months following the termination of the engagement letter.
Guidance, Outlook, and Risks
Closing Date: The Offerings are expected to close on or about January 7, 2025, subject to customary conditions.
Liquidity Risk: The filing explicitly states there is no established trading market for the Warrants, and the Company does not intend to list them. Consequently, the liquidity of the Warrants may be extremely limited.
Management Commentary: The filing does not provide specific operational guidance or outlook beyond the announcement of the capital raise.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $7.0 million gross proceeds.
- Review the impact of the 4,000,001 new shares and potential 8,000,002 warrant shares on existing shareholder dilution.
- Confirm the total cash outflow for placement agent fees (8.0% of gross proceeds plus fixed expenses).
- Assess the liquidity implications of the unregistered Warrants for investors holding them.
- Monitor the 30-day lock-up period on further stock issuances.